Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“ASH Highlights 2026 – Advances in Thrombotic Thrombocytopenic Purpura (TTP)
One of the most impactful sessions today focused on emerging therapeutic strategies in immune TTP (iTTP) and congenital TTP (cTTP), particularly CD38-targeted therapy and recombinant ADAMTS13 replacement.
Daratumumab in Immune TTP (iTTP)
Data from the international, multicenter DarTTP study demonstrated:
- Rapid ADAMTS13 remission in 75% of patients with iTTP who were refractory or intolerant to rituximab and other immunosuppressive therapies
- Sustained remission (>6 months) in approximately two-thirds of responders
- Targeting CD38+ plasma cells offers a promising strategy in cases where B-cell depletion alone is insufficient
These findings represent an important advancement in the management of refractory iTTP and provide renewed hope for patients at high risk of relapse.
Congenital TTP (cTTP)
The session also highlighted a clinical case discussion and phase 3 data on recombinant ADAMTS13 (rADAMTS13) replacement therapy:
- Demonstrated favorable efficacy and safety profile
- Approved in the US, EU, and Japan for both prophylactic and on-demand use
- Represents a paradigm shift in long-term cTTP management, reducing dependence on plasma infusions
This lecture clearly underscored that TTP treatment is entering a new era of mechanism-based and targeted therapy.
Integrating these advances into national practice remains crucial, particularly with regard to laboratory capacity, ADAMTS13 monitoring, and access to innovative therapeutics in our region.”
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion
-
Apr 3, 2026, 17:19Arun V J: Don’t Miss TRANSCON 2026 – A Direct Pathway Into India’s Clinical and Institutional Network
-
Apr 3, 2026, 17:17Louise St. Germain Bannon: Preparating for ISTH 2026 and Highlighting Best Aspects of Congress